Fiche du document
19 novembre 2021
- doi: 10.3390/cancers13225819
- issn: 2072-6694
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.3390/cancers13225819
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/34830973
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/2072-6694
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_6B925EAAEE850
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Mots-clés
dendritic cell; epithelial ovarian cancer; immunotherapy; personalized treatment; vaccinesSujets proches
Carcinoma Cancers Malignancy (Cancer) Malignant tumorsCiter ce document
L.E. Kandalaft et al., « Vaccines as Priming Tools for T Cell Therapy for Epithelial Cancers. », Serveur académique Lausannois, ID : 10.3390/cancers13225819
Métriques
Partage / Export
Résumé
Impressive progress has recently been made in the field of cancer immunotherapy with the adoptive transfer of T cells, a successful personalized strategy, and checkpoint inhibitors (CPI) having extended the survival of numerous patients. However, not all patients have been able to benefit from these innovations. A key determinant of the responsiveness to cancer immunotherapies is the presence of T cells within the tumors. These tumor-infiltrating lymphocytes (TILs) are crucial in controlling tumor growth and their activity is being potentiated by immunotherapies. Although some epithelial cancers are associated with spontaneous T-cell and B-cell responses, which makes them good candidates for immunotherapies, it remains to create strategies that would promote lymphocyte infiltration and enable sustained immune responses in immune-resistant tumors. Therapeutic cancer vaccines hold the potential of being able to render "cold", poorly infiltrated tumors into "hot" tumors that would be receptive to cellular immunotherapies. In this review, we elaborate on the obstacles that need to be overcome and the strategies that are being explored to that end, including various types of antigen repertoires and different vaccine platforms and combinations with other available treatments.